Table 2.

Antiviral activity of BLV against multiple strains of HBV GTA–D enveloped with HDV-1.

	HBV GTA		HBV GTB		HBV GTC		HBV GTD
	HBV construct	EC50 (nM)	HBV construct	EC50 (nM)	HBV construct	EC50 (nM)	HBV construct	EC50 (nM)
EC50 (nM) of individual viral strains	GTA∗	0.65 ± 0.03	GTB∗	0.90 ± 0.29	GTC∗	0.46 ± 0.17	GTD∗	0.49 ± 0.04
	GTA-1	0.17 ± 0.05	GTB-1	0.47 ± 0.06	GTC-1	0.47 ± 0.07	GTD-1	0.29 ± 0.03
	GTA-2	0.88 ± 0.10	GTB-2	0.74 ± 0.19	GTC-2	0.21 ± 0.01	GTD-2	0.20 ± 0.01
	–	–	GTB-3	0.55 ± 0.02	GTC-3	0.71 ± 0.30	–	–
	–	–	GTB-4	0.42 ± 0.19	GTC-4	0.24 ± 0.01	–	–
	–	–	GTB-5	0.41 ± 0.05	GTC-5	0.45 ± 0.08	–	–
	–	–	GTB-6	0.93 ± 0.01	GTC-6	0.28 ± 0.05	–	–
	–	–	GTB-7	0.67 ± 0.04	GTC-7	0.88 ± 0.10	–	–
	–	–	GTB-8	0.55 ± 0.38	GTC-8	0.29 ± 0.04	–	–
	–	–	GTB-9	0.68 ± 0.25	GTC-9	n.a.	–	–
	–	–	GTB-10	0.43 ± 0.07	GTC-10	0.26 ± 0.11	–	–
Mean EC50 (nM)	GTA	0.57	GTB	0.61	GTC	0.42	GTD	0.33
Median EC50 (nM)	GTA	0.65	GTB	0.55	GTC	0.37	GTD	0.29

HBVs/HDVs were produced by transfection of HuH7 cells and were tested for their sensitivity to BLV in PHHs. Mean and median values from replicate experiments are shown.

BLV, bulevirtide; GTA–D, genotypes A–D; HDV-1, HDV genotype 1; n.a., not applicable owing to low infectivity; PHH, primary human hepatocyte.

^∗Representative sequences for each genotype.